Dr. Lei Zhao 赵磊
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Concurrent chemoradiotherapy for esophageal cancer, radiotherapy for thymic tumors, combined chemoradiotherapy for lung cancer, and stereotactic body radiation therapy for liver cancer.
Dr. Zhao holds a medical doctorate and is a Chief Physician and doctoral supervisor at Sun Yat-sen University Cancer Center. Dr. Zhao worked at the Duke University Cancer Center from March 2017 to May 2018. Dr. Zhao became a master's supervisor in April 2017 and a doctoral supervisor in December 2018. Dr. Zhao is a member of the International Society for Diseases of the Esophagus (ISDE) and the China Anti-Cancer Association.
Professional roles
- Standing Committee Member, Oncology Prevention and Control Professional Committee, Guangdong Preventive Medicine Association
- Member, Comprehensive Treatment Professional Committee, Guangdong Liver Disease Society
Name order: in Chinese the family name comes first (Zhao Lei). Papers usually list the name as Lei Zhao or Zhao L.
Selected publications
57 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Natl Cancer Cent, 2025 (senior author): A novel risk stratification system for primary small-cell carcinoma of the esophagus: indication for prognostication and staging. PubMed 40265098
- Int J Radiat Oncol Biol Phys, 2023 (senior author): A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial. PubMed 37210047
- PeerJ, 2023 (senior author): A novel immune-related prognostic signature based on Chemoradiotherapy sensitivity predicts long-term survival in patients with esophageal squamous cell carcinoma. PubMed 37609436
- Biomed J, 2023 (senior author): Trafficking protein TMED3 promotes esophageal squamous cell carcinoma. PubMed 35358714
- BMC Cancer, 2023 (senior author): Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. PubMed 36765311
- Cancer Med, 2022 (senior author): Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. PubMed 35434962
- BMC Cancer, 2022 (senior author): Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis. PubMed 36115960
- Mol Ther Nucleic Acids, 2021 (senior author): miR-181a, delivered by hypoxic PTC-secreted exosomes, inhibits DACT2 by downregulating MLL3, leading to YAP-VEGF-mediated angiogenesis. PubMed 33898109
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion